Inhibition of 2C Coxsackie B Virus Protein to Decrease Pathogenicity of Diabetes Mellitus Type 1.


Journal

Current computer-aided drug design
ISSN: 1875-6697
Titre abrégé: Curr Comput Aided Drug Des
Pays: United Arab Emirates
ID NLM: 101265750

Informations de publication

Date de publication:
2020
Historique:
received: 08 03 2019
revised: 27 06 2019
accepted: 01 08 2019
pubmed: 21 8 2019
medline: 7 4 2021
entrez: 21 8 2019
Statut: ppublish

Résumé

Insulin-dependent Diabetes Mellitus Type 1 (T1D) also referred to as autoimmune diabetes. T1D is a chronic disease which is characterized by way of insulin deficiency. The deficiency is due to the loss of pancreatic β cells and leads to hyperglycemia. There are many factors which play a significant role in T1D disease pathogenicity including genetic predisposition, the immune system, and environmental factors. The environmental factors may include Coxsackie B4 virus, a small RNA virus. The objective of current in silico study is to identify active lead compounds against Coxsackie B4 virus, a small RNA virus which has been reported in diabetic patients after PCR. There is a need to predict inhibitors against TID caused by Coxsackie B4 viral protein that may be used as a drug against TID in the future. For this purpose, different bioinformatics databases and tools were used. The protein structure generation and validation, retrieval of ligands and their properties analysis were performed by different databases, web servers, and software tools. Moreover, the docking tools were used to identify the target site of the protein and interaction of different inhibitors with the target protein molecule. Based on the analysis, two lead compounds ZINC00034488 and ZINC00034585 were selected as potential drugs. These compounds are non-toxic and have best interaction energy and fulfill Lipinski rule, Veber rule, Ghose Rule, Weighted QED, Unweighted QED and BBB likeness parameters. Our work will help researchers to get an idea about the understanding of chemicals against Coxsackie B4 Viruses and helpful to design a drug and test these chemicals to overcome Diabetes Mellitus Type 1 caused by Coxsackie B4 virus.

Sections du résumé

BACKGROUND BACKGROUND
Insulin-dependent Diabetes Mellitus Type 1 (T1D) also referred to as autoimmune diabetes. T1D is a chronic disease which is characterized by way of insulin deficiency. The deficiency is due to the loss of pancreatic β cells and leads to hyperglycemia. There are many factors which play a significant role in T1D disease pathogenicity including genetic predisposition, the immune system, and environmental factors. The environmental factors may include Coxsackie B4 virus, a small RNA virus.
OBJECTIVE OBJECTIVE
The objective of current in silico study is to identify active lead compounds against Coxsackie B4 virus, a small RNA virus which has been reported in diabetic patients after PCR. There is a need to predict inhibitors against TID caused by Coxsackie B4 viral protein that may be used as a drug against TID in the future.
METHODS METHODS
For this purpose, different bioinformatics databases and tools were used. The protein structure generation and validation, retrieval of ligands and their properties analysis were performed by different databases, web servers, and software tools. Moreover, the docking tools were used to identify the target site of the protein and interaction of different inhibitors with the target protein molecule.
RESULTS RESULTS
Based on the analysis, two lead compounds ZINC00034488 and ZINC00034585 were selected as potential drugs. These compounds are non-toxic and have best interaction energy and fulfill Lipinski rule, Veber rule, Ghose Rule, Weighted QED, Unweighted QED and BBB likeness parameters.
CONCLUSION CONCLUSIONS
Our work will help researchers to get an idea about the understanding of chemicals against Coxsackie B4 Viruses and helpful to design a drug and test these chemicals to overcome Diabetes Mellitus Type 1 caused by Coxsackie B4 virus.

Identifiants

pubmed: 31429693
pii: CAD-EPUB-100361
doi: 10.2174/1573409915666190820154422
doi:

Substances chimiques

Antiviral Agents 0
Carrier Proteins 0
Viral Nonstructural Proteins 0
2C protein, viral EC 3.6.1.-

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

318-326

Informations de copyright

Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Auteurs

Amina Amin (A)

Department of Biosciences, COMSATS University Islamabad, Sahiwal Campus, Sahiwal, Pakistan.

Muhammad A Rasheed (MA)

Department of Biosciences, COMSATS University Islamabad, Sahiwal Campus, Sahiwal, Pakistan.

Rana A Diwan (RA)

Department of Community Medicine, Sahiwal Medical College, Sahiwal, Pakistan.

Muhammad Shahid (M)

Government Mian Meer THQ Hospital, Lahore, Pakistan.

Saddia Bano (S)

Research Center for Modeling and Simulations, National University of Sciences and Technology, Islamabad, Pakistan.

Adnan Riaz (A)

School of Computer Science and Technology, Dalian University of Technology, Dalian, China.

Muhammad N Iqbal (MN)

Department of Biosciences, COMSATS University Islamabad, Sahiwal Campus, Sahiwal, Pakistan.

Muhammad W Sajid (MW)

Department of Biosciences, COMSATS University Islamabad, Sahiwal Campus, Sahiwal, Pakistan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH